- Early Bird
- Posts
- Johnson & Johnson Stock Guide
Johnson & Johnson Stock Guide
Should you invest in the stock now?
![](https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/ecce0c91-f453-4778-bd8c-a41e22d91313/Untitled.jpg?t=1710027121)
Early Bird Prime for May 19, 2024
Pharma stocks have been unpopular over the past year, and Johnson & Johnson (NYSE: JNJ) has been leading the charge in this unpopularity contest.
The stock is down 3.33% in 2024, even as the rest of the market grows.
![](https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/3010ce43-a3de-4f6e-a206-69bbc9032502/Screen_Shot_2024-05-18_at_5.55.34_PM.png?t=1716069344)
The market gave Johnson & Johnson's financial results in mid-April the cold shoulder. Investors were not impressed, and the stock took a hit.
But Johnson & Johnson has been on a comeback tour lately, climbing 7% like a determined mountain goat.
Last week, Johnson & Johnson decided to shake things up by buying dermatology-focused biotech Proteologix. The market reacted positively, sending the stock price up.
And if that wasn't enough excitement, they also exited their spinoff Kenvue (NYSE: KVUE) with a stake sale.
So, with all this good news, you might wonder if now is the time to buy Johnson & Johnson stock. Is the stock the golden ticket to success or another mirage in the desert of investment opportunities? Well, here’s the answer:
![](https://media.beehiiv.com/cdn-cgi/image/format=auto,onerror=redirect/uploads/publication/logo/ff8fd2d7-2a7b-49e5-be47-5405ff69cc1b/thumb_Beehiiv_Logo.jpg)
Subscribe to Early Bird Prime to read the rest.
Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In